Many translated example sentences containing “eritropoyetina recombinante” – English-Spanish dictionary and search engine for English translations. La farmacocinética de la eritropoyetina recombinante humana en pacientes con nefropatía endémica de los Balcanes. The Pharmacokinetics of Recombinant. Efecto del tratamiento con eritropoyetina recombinante humana sobre la necesidad de transfusión sanguínea en los pacientes críticos. Effect of human.

Author: Yozshulabar Nibar
Country: Uzbekistan
Language: English (Spanish)
Genre: Education
Published (Last): 18 September 2010
Pages: 168
PDF File Size: 9.65 Mb
ePub File Size: 3.21 Mb
ISBN: 219-5-96231-526-3
Downloads: 34994
Price: Free* [*Free Regsitration Required]
Uploader: Julkree

Ingredient matches for Eritropoyetina Humana Recombinante Delta Erythropoietin Erythropoietin is reported as an ingredient of Eritropoyetina Humana Recombinante Delta in the following countries: Further information Always recombinane your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Pavlovic-Kentera V, Djukanovic Lj.

Eritropoyetina Humana Recombinante Delta –

Show all Show less. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: CiteScore measures average citations received per document published.

Renal function, protein excretion and pathology of Sritropoyetina endemic nephropathy. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. All works go through a rigorous selection process.

SNIP measures contextual recombihante impact by wighting citations based on the total number of citations in recombinajte subject field. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. Anaemia in Balkan endemic nephropathy. Pharmacokinetics studies were mostly devoted to the pharmacokinetics of diverse ESA administered by different routes, as well as to the pharmacokinetics of ESA in various groups of chronic kidney disease patients and healthy persons.


No significant differences between groups were found in maximal Epo concentration, time to maximum Epo concentration, area under the curve from time of dosing extrapolated to infinity, clearance, mean residence time of Epo between groups both before and after adjustment. SRJ is a prestige metric based on the idea that not all citations are the same. The relevant pharmacokinetic parameters were calculated after noncompartmental pharmacokinetic efitropoyetina using Kinetica software Thermo Scientific, ver.

The prospective clinical study was performed according to good clinical practice and in accordance with the Declaration of Helsinki in three clinical centers.

Delayed massive cerebral fat embolism secondary to severe polytrauma. Comparison of the pharmacokinetics of beta-erythropoietin given subcutaneously to hemodialysis patients with BEN or other kidney diseases non-BEN. The main limitation of our study was the small number of patients in each group, and they were not matched in age. Our patients had iron reserves above the upper limit of normal and a similar proportion of subjects from each eritroppoyetina used iron supplements.

The easiest way to lookup drug information, identify pills, check interactions recomvinante set up your own personal medication records. Impact of elevated C-reactive protein levels on erythropoiesis stimulating agent ESA dose and responsiveness in hemodialysis patients.

Methods Study design and patients The prospective clinical study was performed according to good clinical practice and in accordance with the Declaration of Helsinki in three clinical centers. The significance of differences between mean values for groups was calculated using the Mann-Whitney U test and Student’s t-test.


Introduction Anemia was described as a characteristic of Balkan endemic nephropathy BEN in early reports on the disease, 1,2 so Danilovic 3 included it among the criteria for diagnosis. Previous article Next article. Noncompartmental pharmacokinetic analysis using Kinetica software Thermo Scientific, ver.

Eritropoyetina recombinante humana en la insuficiencia renal crónica

Pharmacokinetic analysis of beta-erythropoietin detected a significantly longer elimination half-life in BEN than in non BEN patients.

J Am Soc Nephrol ; Population pharmacokinetics and pharmacodynamics of peptidic erythropoiesis receptor agonist ERA in healthy volunteers. Beta-erythropoietin administration and blood sampling. Reduced production, absorption, and elimination of erythropoietin in uremia compared with healthy volunteers.

Recent studies were largely devoted to the pharmacokinetics of new ESAs 10,12,14 and were usually carried out in healthy persons.


J Clin Pharmacol The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two receding years. Renal Injury from Drugs and Chemicals, third edition. Despite long clinical experience with ESAs, the mechanisms eritripoyetina in their elimination have not been fully elucidated.

The pharmacokinetics of recombinant human erythropoietin after subcutaneous injection at different sites. The authors declare that they have no conflicts of interest related to the contents of this article.